全文获取类型
收费全文 | 473篇 |
免费 | 21篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 34篇 |
妇产科学 | 12篇 |
基础医学 | 41篇 |
口腔科学 | 11篇 |
临床医学 | 58篇 |
内科学 | 92篇 |
皮肤病学 | 3篇 |
神经病学 | 14篇 |
特种医学 | 9篇 |
外科学 | 98篇 |
综合类 | 5篇 |
预防医学 | 13篇 |
眼科学 | 27篇 |
药学 | 25篇 |
肿瘤学 | 49篇 |
出版年
2023年 | 7篇 |
2022年 | 9篇 |
2021年 | 23篇 |
2020年 | 7篇 |
2019年 | 20篇 |
2018年 | 16篇 |
2017年 | 10篇 |
2016年 | 21篇 |
2015年 | 22篇 |
2014年 | 37篇 |
2013年 | 39篇 |
2012年 | 39篇 |
2011年 | 29篇 |
2010年 | 21篇 |
2009年 | 16篇 |
2008年 | 26篇 |
2007年 | 25篇 |
2006年 | 29篇 |
2005年 | 26篇 |
2004年 | 21篇 |
2003年 | 12篇 |
2002年 | 15篇 |
2001年 | 6篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 3篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有496条查询结果,搜索用时 609 毫秒
91.
Yildiz F Zengin N Engin H Güllü I Barista I Caglar M Ozyar E Cengiz M Gürkaynak M Zorlu F Caner B Atahan IL Tekuzman G 《International journal of radiation oncology, biology, physics》2004,60(3):839-846
PURPOSE: To determine the efficacy and toxicity of combined modality treatment (CMT) or radiotherapy (RT) alone in the management of clinical Stage I-IIA adult Hodgkin's disease patients. METHODS AND MATERIALS: Forty-seven patients with supradiaphragmatic clinical Stage I-IIA Hodgkin's disease without bulky mediastinal lymphadenopathy were enrolled into this prospective study between September 1997 and February 2002. Patients with very favorable criteria presenting with one or two nonbulky nodal areas involved, an erythrocyte sedimentation rate of <50 mm/h, age <40 years, and either lymphocyte predominant or nodular sclerosing histologic findings were treated by RT alone. Patients missing any of these favorable criteria were classified as the other favorable group and were treated with three courses of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy followed by involved-field RT. The median age was 36 years (range, 19-53 years). Of the 47 patients, 15 were women and 32 were men. Only 3 patients were classified as the most favorable group and treated with mantle RT alone; the remaining 44 were treated with CMT. RESULTS: The median follow-up was 51 months (range, 20-74 months). Only 2 patients developed recurrence, both out of the irradiated field, one in the contralateral neck and the other in the abdomen. The 5-year relapse-free and overall survival rate was 95.4% and 97.8%, respectively. Although none of the prognostic factors were statistically significant for relapse-free survival, a trend was noted for the response to chemotherapy (p = 0.06). Only 2 patients developed treatment-related complications. One patient treated with mantle RT alone developed severe ischemic heart disease and one in the CMT arm developed subclinical hypothyroidism. CONCLUSION: Despite the short follow-up, CMT or RT alone tailored according to the clinical prognostic factors were successful in terms of disease control in clinical Stage I-IIA Hodgkin's disease. Longer follow-up is required to make definitive conclusions. 相似文献
92.
The incidence of mechanical and infectious complications of totally implantable central venous access devices (TIDs) must be related to underlying disease, intensity of the chemotherapy, and frequency of manipulations. Records of the patients hospitalized from January 2002 to May 2005 were evaluated. Patients with TIDs were matched with patients without TIDs having the same malignancy and the same anti-neoplastic chemotherapy. Catheter-related complications were documented and corresponding phases of the chemotherapy in matched pairs were compared with regard to infections. TIDs were inserted in 31 patients with a median age of 4.3 years (22 acute leukemia, 1 NHL, and 8 solid tumors). Total number of catheter days was 5268, with a median catheter life of 174 days (range 9-493 days). Nine catheters (29%) were removed due to mechanical and infectious complications. There was 13 catheter-related infections with a rate of 2.46/1000 catheter days. Total number of mechanical complications was 5 and overall rate of complications was 3.41/1000 catheter days. The rate of febrile episodes was 54 and 41 in the TID and no TID group, respectively (p: .11). Duration of neutropenia was 9.6 and 7.4 days and duration of fever per febrile attack was 5.6 and 4.4 days in the TID and no TID group, respectively (p: .047 and .56). Although most of the patients in this study had hematological malignancy and required frequent manipulation, the results were similar to those in developed countries. TIDs are essential for management of chemotherapy in pediatric malignancies with acceptable complications. 相似文献
93.
The purpose of this study was to compare the efficacy, safety, and cost of piperacillin/tazobactam with cefepime monotherapy in children with febrile neutropenia. A prospective randomized study in children and adolescent with cancer was conducted. Patients were randomly assigned to receive either 80 mg/kg piperacillin/10 mg/kg tazobactam every 6 h (maximum 4.5 g/dose) or cefepime 50 mg/kg every 8 h (maximum 2 g/dose). Treatment modification was defined as all the changes in the empirical antimicrobials after the first 96 h. Overall treatment success was defined as cure of febrile episode with or without modification. Cost of hospitalization, antimicrobial drugs, and supportive therapy were calculated. Fifty febrile netropenic episodes (25 in the piperacillin/tazobactam group, 25 in the cefepime group) in 27 pediatric cancer patients were evaluated. The groups were comparable in terms of age, gender, body weight, primary diagnosis, disease status, initial neutrophil count, and duration of neutropenia. Microbiologically and clinically documented infection rate was 46%. There was no infection-related mortality in the study period. The treatment success of initial empirical therapy without modification was not different in the 2 groups (56% in piperacillin/tazobactam group and 48% in cefepime group). Anti-anaerobic drugs were added more frequently in the cefepime group. Duration of fever, neutropenia, treatment, and cost of therapy were not different in the treatment groups. Piperacillin/tazobactam monoterapy is as effective as cefepime monotherapy in febril neutropenia of pediatric cancer patients. 相似文献
94.
Nuriye Yıldırım Özdemir Hüseyin Abalı Berna Öksüzoğlu Burçin Budakoğlu İlkay Akmangit Nurullah Zengin 《Supportive care in cancer》2009,17(4):399-403
Goals It is generally recommended to wait for at least 24 h before starting chemotherapy after implanting venous port catheters
(VPC). Our aim was to evaluate whether it is safe to start chemotherapy on the day of implantation.
Patients and methods One hundred eighty patients who had to be given chemotherapy on the day of VPC implantation at our institution from June 2005
to April 2007 were included.
Main results Of patients, 122 were male (67.8%) and median age was 55 years. Majority (133, 72.8%) had colon and gastric adenocancer. Median
time to chemotherapy onset from VPC implantation was 102 min (minimum–maximum, 12–402). One hundred sixty-four (91.1%) received
prolonged chemotherapy infusions beyond 48 h. No life-threatening acute complications like pneumothorax and hemothorax developed.
In one patient extravasation (empty saline extravasation secondary to wrong insertion of the needle), in 17 (9.4%) pain, and
in 41 (22.8%) minor bleeding as echymosis were seen. Thrombosis developed in 11 (6.1%). Reasons for VPC removal were thrombosis
(2), sepsis (2), cellulitis (1), skin dehiscence (1), and patient will (1).
Conclusion Chemotherapy administration immediately after VPC implantation appears safe without increased acute and chronic complications
in inpatient setting. 相似文献
95.
96.
97.
Fulva Kamit Can Ayse Berna Anil Murat Anil Neslihan Zengin Alkan Bal Yuksel Bicilioglu Gamze Gokalp Fatih Durak Gulberat Ince 《Indian pediatrics》2017,54(10):835-840
Objective
To analyze the change in quality indicators due to the use of high-flow nasal cannula therapy as a non-invasive ventilation method in children with respiratory distress/failure in a non-invasive ventilation device-free pediatric intensive care unit.Methods
Retrospective chart review of children with respiratory distress/failure admitted 1 year before (period before high-flow nasal cannula therapy) and 1 year after (period after high-flow nasal cannula therapy) the introduction of high-flow nasal cannula therapy. We compared quality indicators as rate of mechanical ventilation, total duration of mechanical ventilation, rate of reintubation, pediatric intensive care unit length of stay, and mortality rate between these periods.Results
Between November 2012 and November 2014, 272 patients: 141 before and 131 after high-flow nasal cannula therapy were reviewed (median age was 20.5 mo). Of the patients in the severe respiratory distress/failure subgroup, the rate of intubation was significantly lower in period after than in period before high-flow nasal cannula therapy group (58.1% vs. 76.1%; P<0.05). The median pediatric intensive care unit length of stay was significantly shorter in patients who did not require mechanical ventilation in the period after than in the period before high-flow nasal cannula therapy group (3d vs. 4d; P<0,05).Conclusions
Implementation of high-flow nasal cannula therapy in pediatric intensive care unit significantly improves the quality of therapy and its outcomes.98.
99.
100.
Nuriye Yıldırım Özdemir Hüseyin Abalı Berna Öksüzoğlu Burçin Budakoglu Doğan Uncu Tunç Güler Hatice Odabaşı Nurullah Zengin 《Medical oncology (Northwood, London, England)》2010,27(3):680-684
Patients with advanced gastric carcinoma have still had bad prognosis despite advances in the modern treatment era. Docetaxel,
cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases. In this study, we modified the
standard doses of DCF (mDCF) to evaluate the effectiveness and side effects. From July 2005 to July 2008, 37 advanced gastric
cancer patients treated with at least one course of mDCF protocol as first-line treatment were included. The mDCF protocol
included 60 mg/m2 docetaxel and cisplatin for 1 day and 600 mg/m2/day, 5-flourouracil infusion for 5 days, repeated every 3 weeks. No patients used prophylactic granulocte -colony stimulating
factor. Of the patients, 28 were male and nine were female; the median age was 53 (23–65) years. Of them, 83.8% received at
least four courses of chemotherapy and 64.9% completed the preplanned six courses of treatment. Eleven (29.7%) of those patients
who received mDCF in the first-line treatment used the FOLFIRI (5-FU, folinic acit, irinotekan) regimen for the second-line
treatment. Response rates were evaluated according to RECIST criteria in 30 out of 37 patients. The median follow-up time
was 7.1 months. The longest follow-up time was 19.9 months. Two patients (5.4%) had complete response, nine (21.6%) had partial
response, and 14 (37.9%) had stabilized disease; overall, the disease was controlled in 25 patients (64.9%) whereas five patients
(13.5%) had progression. Median time to progression was 6.7 months and overall survival was 10 months. The assessment of patients
for grade 3–4 toxicity revealed that while 5.4% had anemia and 8.1% had neutropenia, 5.4% nausea and 5.4% diarrhea. Neutropenic
fever developed in two patients, requiring hospitalization. G-CSF was used in three patients. Two patients with neutropenic
fever and two with severe anemia (total number 4; 10.8%) received delayed chemotherapy. Dose reduction was required in four
patients (10.8%), one due to neutropenia, one due to nephrotoxicity, and two due to nausea. No patient died due to chemotherapy
toxicity. This retrospective study suggested that mDCF might have comparable efficacy with classical DFC, with better toxicity
profile. However, its small size and retrospective nature should be considered when interpreting the results. 相似文献